Effectiveness and Safety of Once‐Weekly Semaglutide 2.4 mg in Korean Adults With Obesity or Overweight: A Multicenter Retrospective Real‐World Study (RE‐SEMA‐K Study)
Diabetes/Metabolism Research and Reviews · 2026-11 · 42 (8)
DOI: 10.1002/dmrr.70242 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Diabetes/Metabolism Research and Reviews, online erschienen am 09.11.2026. Verfasst von Yu-Jin Kwon und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Family Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Republic of Korea. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Obesity, Overweight, Weight Loss. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Society for Korean Obesity and Metabolism Studies..
Abstract (Originalsprache)
Aims
To evaluate the effectiveness and treatment patterns of once‐weekly semaglutide 2.4 mg in South Korean adults with overweight or obesity in real‐world practice. Materials and Methods This multicenter retrospective study analysed electronic medical records from 17 centres in South Korea. Included were adults (≥ 19 years) with BMI ≥ 25 kg/m 2 , or ≥ 23 kg/m 2 with obesity‐related comorbidities. Primary endpoints were changes in body weight at 3, 6, 9, and 12 months. Secondary outcomes included body composition, categorical weight loss, cardiometabolic changes, treatment persistence, safety, and changes in liver function.
Results
Among 1160 patients (40.9% with prior obesity medications), semaglutide treatment induced progressive weight reduction (−5.85%, −9.55%, −11.43%, and −13.16% at 3, 6, 9, and 12 months). Greater reduction occurred in women, younger patients, and those without T2D or prior obesity medication. By 6 months, cardiometabolic, liver function, and body composition parameters improved, with preferential loss of fat over lean mass (all p < 0.001). Starting doses varied across patients (0.25 mg, 55.9%; 0.5 mg, 30.4%; 1.0 mg, 11.9%), with rapid dose escalation reaching the maintenance dose (2.4 mg) in a mean of 3.52 months, reflecting individualised real‐world dosing. Mean treatment duration was 4.9 months. Adverse events, predominantly transient gastrointestinal symptoms, occurred in approximately 22% of patients.
Conclusions
Semaglutide 2.4 mg achieved substantial weight loss in South Korean adults with overweight or obesity. Weight reduction was comparable to the STEP 6 trial despite shorter follow‐up (4.9 months), substantial prior obesity medication exposure, and accelerated dose escalation, supporting robust real‐world effectiveness.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Family Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Republic of Korea.
- Department of Family Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea.
- Department of Family Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, Republic of Korea.
- Department of Family Practice and Community Health, Ajou University School of Medicine, Suwon, Republic of Korea.
- Department of Family Medicine, Daegu Catholic University School of Medicine, Daegu, Republic of Korea.
- Department of Family Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu, Republic of Korea.
ORCID-Profile: Yu-Jin Kwon, Young-Sang Kim, Hae-Jin Ko, Susie Jung, Yoon Jeong Cho, Ji-Eun Song, Ga Eun Nam, Jungha Park, Myung Jae Seo, Yeong Sook Yoon, Yonghwan Kim, Seung Hee Kim, Yong Ho Lee, Seok-Jae Heo, Jee-Hyun Kang, Kyoung-Kon Kim
Förderung
- Society for Korean Obesity and Metabolism Studies.
Zitieren
APA
Kwon, Y. J., Kim, Y. S., Ko, H. J., Jung, S., Cho, Y. J., Song, J. E., Lee, S. B., Nam, G. E., Park, J., Seo, M. J., Kim, J. K., Kang, S. Y., Yoon, Y. S., Cho, S. H., Kim, Y., An, H. J., Kim, S. H., Seo, Y. B., Lee, Y. H., …, & Kim, K. K. (2026). Effectiveness and Safety of Once‐Weekly Semaglutide 2.4 mg in Korean Adults With Obesity or Overweight: A Multicenter Retrospective Real‐World Study (RE‐SEMA‐K Study). Diabetes/Metabolism Research and Reviews, 42(8). https://doi.org/10.1002/dmrr.70242
Vancouver
Kwon YJ, Kim YS, Ko HJ, Jung S, Cho YJ, Song JE, et al. Effectiveness and Safety of Once‐Weekly Semaglutide 2.4 mg in Korean Adults With Obesity or Overweight: A Multicenter Retrospective Real‐World Study (RE‐SEMA‐K Study). Diabetes/Metabolism Research and Reviews. 2026;42(8). doi:10.1002/dmrr.70242
BibTeX
@article{Kwon2026,
author = {Kwon, Yu-Jin and Kim, Young-Sang and Ko, Hae-Jin and Jung, Susie and Cho, Yoon Jeong and Song, Ji-Eun and Lee, Sung-Bum and Nam, Ga Eun and Park, Jungha and Seo, Myung Jae and Kim, Jong Koo and Kang, Seo Young and Yoon, Yeong Sook and Cho, Soo Hyun and Kim, Yonghwan and An, Hye-Ji and Kim, Seung Hee and Seo, Yoo-Bin and Lee, Yong Ho and Heo, Seok-Jae and Kang, Jee-Hyun and Kim, Kyoung-Kon},
title = {Effectiveness and Safety of Once‐Weekly Semaglutide 2.4 mg in Korean Adults With Obesity or Overweight: A Multicenter Retrospective Real‐World Study (RE‐SEMA‐K Study)},
journal = {Diabetes/Metabolism Research and Reviews},
year = {2026},
volume = {42},
number = {8},
doi = {10.1002/dmrr.70242}
}
EUVIMED